NCT07103369View on ClinicalTrials.gov

A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

March 24, 2025

Study Completion Date

March 31, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

SM17 for injection

SM17 monoclonal antibody for intravenous infusion use

OTHER

SM17 placebo for injection

placebo to be compared with SM17, excipient solution of SM17 monoclonal antibody without protein

Trial Locations (1)

Unknown

The First Hospital of China Medical University, Shenyang

All Listed Sponsors

lead

SinoMab BioScience Ltd

INDUSTRY

NCT07103369 - A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter